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Hydroxyurea is an antitumoral drug that acts as an inhibitor of ribonucleotide reductase, an enzyme 
essential for DNA synthesis. It is used in the treatment of Philadelphia-chromosome negative 
mieloproliferative syndromes, sickle cell disease, psoriasis, some solid cancers and in the treatment of 
HIV infection. 
 
Due to its direct cytotoxicity and its photosensitising action, Hydroxyurea is responsible for a wide 
spectrum of cutaneous side effects. These include: xerosis, ichthyosis, skin atrophy, facial erythema, 
palmoplantar keratoderma, alopecia, skin hyperpigmentation, dermatomyositis-like eruptions, 
onychodystrophy, melanonychia, actinic keratoses, squamous cell carcinomas and leg ulcers which are 
a rare but severe long-term adverse effect of hydroxyurea therapy. 
 
Hydroxyurea-induced leg ulcers appear usually as small, well-defined, shallow ulcers with an adherent, 
yellow, fibrinous necrotic wound bed. They are typically found in the perimalleolar region but also on 
the heel, dorsum of the foot and the toes;  occasionally forearms, hands and face can be affected. 
Lesions are often multiple and bilateral. A constant finding is an extreme, difficult-to-treat pain 
accompanying the ulcerations. The withdrawal of the drug generally leads to spontaneous healing of 
these lesions. 
 
Care providers have scarce awareness of this cutaneous side effect and late or wrong diagnoses are 
frequent. Indeed, regular dermatologic screening should be performed on patients treated with 
hydroxyurea. 
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Abstract 
Hydroxyurea is an antitumoral drug mainly used in the treatment of Philadelphia 
chromosome-negative myeloproliferative syndromes and sickle-cell disease. Ulcers 
represent a rare but severe long-term adverse effect of hydroxyurea therapy. 
Hydroxyurea-induced ulcers are often multiple and bilateral, typically developing in the 
perimalleolar region, although any cutaneous district is potentially affected. They generally 
look small, well-defined, shallow with an adherent, yellow, fibrinous necrotic base. A 
constant finding is also an extremely intense, treatment-resistant pain accompanying these 
ulcerations. Withdrawal of the drug generally leads to spontaneous healing of these 
lesions.  
Care providers tend to show insufficient awareness of this highly debilitating cutaneous 
side effect, and late or missed diagnoses are frequent. Instead, regular dermatologic 
screening should be performed on hydroxyurea-treated patients.  
This article will present a comprehensive review of indexed case reports and clinical 
studies, followed by a discussion about treatment options aiming at increasing knowledge 















Cutaneous ulcers represent a pathology typical of the lower limb, due to the anatomy of its 
terminal circulation, and are usually caused by arterial insufficiency, venous stasis or 
metabolic diseases such as diabetes. Ulcers are common as well in myeloproliferative 
disorders (MPDs) and in sickle cell disease (SCD), due to the alteration of microcirculation 
typical in these conditions (1). Also drugs, including hydroxyurea (HU), can be a rare 
cause of ulcers (2). 
 
Hydroxyurea pharmacological properties and mechanisms of action 
 
HU or hydroxycarbamide, firstly synthesized in 1869 by Dresler and Stein from 
hydroxylamine and hydrogen cyanate (3-4), is a non-alkylating hydroxylated urea analog 
with antineoplastic and antiviral properties (5). It is indicated in the treatment of 
Philadelphia-chromosome negative myeloproliferative syndromes (MPs), sickle cell 
disease (SCD), psoriasis (6), some solid cancers and it was proposed in combination with 
antiretroviral drugs in the therapy of HIV infection (7). 
HU is an easily absorbed drug and reaches peak blood levels 1–2 hours after ingestion. It 
has an almost complete bioavailability and distributes in the water compartments of the 
body so that intravenous administration is usually unnecessary. It can cross the blood–
brain barrier and the placenta, and can be found in breast milk. i t  is eliminated mainly 
through the kidneys (5). 
HU was a pioneer drug in the treatment of solid cancer, but unlike the other first 
generation-chemotherapeutics is not a metabolite analog; it is instead a non-competitive 
inhibitor of the enzyme ribonucleotide reductase (RR), which is essential for the 
synthesis of deoxyribonucleotides from ribonucleotides. Inhibition of RR results in 
depletion of desoxyribonucleotides (dNTPs), cessation of DNA synthesis and death of 
S-phase cells. M o r e o v e r , HU can bind and inhibit another enzyme, histone 
deacetilase, t h u s  inducing differentiation of tumoral cells via c-jun expression (8). 
Also, HU induces sensitization of tumors to other chemotherapeutic agents through a yet 
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different mechanism: the depletion of dNTPs facilitates the activity of pyrimidine and 
purine antimetabolites; RR also plays a role in DNA repair, therefore HU is associated 
with dsDNA breaks; HU could possibly help reverse acquired tumoral resistance to 
chemiotherapy promoting loss of extrachromosomal-amplified genes (5). 
 
Hydroxyurea systemic and dermatological side effects 
 
Despite its reputation of being a safe drug, the reported adverse events during HU 
treatment are numerous and concerning different body systems; not surprisingly, tissues 
with high cell turnover are the most affected by the cytostatic action of HU. 
HU can affect bone marrow causing myelosuppression, bleeding and, rarely, leukemic 
transformation. B12 or folate-unrelated macrocytosis can occur. Oral mucosal ulcerations 
and pigmentation, accompanied by nausea and vomiting, epigastric pain and diarrhea 
represent the most common reported gastrointestinal side effect of HU therapy (5-9). 
Ulcers of genital mucosa have also been described (10,11). High fever outbreak 
sometimes associated with maculopapular rash and abnormal liver function tests (12), 
pneumonitis and bronchiolitis obliterans (13), vasculitis (14) and gangrene in toes (15-16) 
have also been reported in literature as HU possible adverse effects.  
HU therapy has been associated with multiple cutaneous alterations (Table 1) such as 
xerosis, scaling, atrophy of the skin and subcutaneous tissues, skin hyperpigmentation, 
facial a n d  a c ra l  erythema, palmoplantar keratoderma, solar hypersensitivity with 
eruptive appearance of squamous cell and basal cell carcinomas on sun-exposed sites, 
partial non-cicatricial alopecia, nail alterations and cutaneous ulcers (Fig. 1) (17).  
To this range of cutaneous complications should also be added a characteristic 
eruption, unique to patients affected by hematologic malignancies, described in the 
literature through multiple names: lichen planus-like lesions (18,19), dermatomyositis-
like lesions, pseudo-dermatomyositis, Gottron-like papules, dermatomyositis without 
myositis (20-23) as well as being associated with graft-versus-host disease (24). Daoud 
proposed r e c e n t l y  the definition of hydroxyurea dermopathy for this unique 
nosological entity (25). It is characterized by a poikilodermatous eruption with 
telangiectasia, erythema, scaling, and lichenoid papules resembling Gottron‟s papules 
of dermatomyositis, usually on the dorsa of hands and knuckles.  
HU-induced non-melanoma skin cancer usually occurs in clear Fitzpatrick phototype-
patients affected by hematologic malignancies. HU expresses its carcinogenic potential 
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by preventing the repair of light exposition-induced DNA damage, thus leading to cellular 
dysregulation and solar hypersensitivity, with spectrum of skin changes that extends from 
sunburn to non-melanoma skin cancers (26). The presence of Bowen‟s disease and 
multiple actinic keratoses in sun-exposed areas that can evolve to multiple aggressive 
squamous cell carcinomas (27,28) is typical. The category of “HU-associated squamous 
dysplasia” has been used to describe these premalignant lesions (28).  
Nail changes are probably an underestimated finding in patients on hydroxyurea. 
They include onychodystrophy, generalized hyperpigmentation (melanonychia), 
longitudinal bands and blue lunulae. Nail dyschromy develops predominantly in female 
patients and the thumb and index fingernails appear to be the most frequently 
affected sites. Longitudinal bands are the most common pattern, while transverse 
melanonychia is probably related to intermittent courses of chemotherapy, due to the 
direct toxic effect on the nail matrix. These changes have been variably related to 
genetic predisposition, the toxic effect of hydroxyurea on the nail bed and matrix, 
photosensitization, and focal stimulation of melanocytes at the matrix level (29-30). 
Cutaneous ulcers during HU therapy, firstly described by Stahl and Silber in 1985 (31), 
are still today a poorly recognized side effect of this drug, despite them alone 
accounting for 30% of all dermatologic adverse events reported to the manufacturer 
worldwide (1). Their prevalence in clinical studies i s  va r i ab le :  f r om 3 , 5% -5%  in  
l a rge  coh o r t  s tud ie s  ( 32-35) t o  8 ,5 -1 0%  o r  e ven  m o re  i n  s tud ie s  w i t h  
sma l le r  n umbe rs  o f  pa r t i c i pa n t s  ( 3 6 -4 3 ) .  Due to their impact on treated 
patients‟ health and quality of life, cutaneous and mucosal ulcers, together with fever, 
pneumonitis and any mucocutaneous alterations unacceptable for the patient, were 
recently included by an international consensus conference in the definition of clinical 
intolerance to HU (35,43).  
 
Clinical feature and pathogenesis of hydroxyurea associated cutaneous ulcers 
 
Hydroxyurea-induced cutaneous ulcers are usually small, well-defined and shallow with 
an adherent, yellow, fibrinous necrotic base (Fig. 2) (44). They are typically found in the 
perimalleolar region but also on the lower leg, heel, dorsal foot and toes; occasionally 
forearms, hands and face can be affected (35). Skin lesions are often multiple and 
bilateral. Lesions are surrounded by a livid erythema and areas of small white scars 
called atrophie blanche (2). A constant finding is an extremely intense, treatment-
resistant pain accompanying these ulcerations, often requiring the administration of 
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opioids. Extension of such lesions seems directly correlated in the individual patient to HU 
dosage (1). The histology of the lesion is usually aspecific, but may show epidermal 
atrophy, dermal fibrosis, scar tissue without vasculitis and, occasionally, fibrinoid thrombi 
(table 3) (45). 
The mechanisms underlying the pathogenesis of the HU-associated cutaneous ulcer are 
not clearly defined, but probably various different elements play a role in their 
occurrence (Fig. 3) (46). Defective repair mechanisms in skin basal cells due to HU 
cytotoxicity undoubtedly plays a role in the formation of leg ulcers as well in the 
pathogenesis of all dermatologic HU side effects. Long term HU therapy leads to 
cumulative cytotoxicity for the basal cells of the epidermis, due to inhibition of DNA 
synthesis and formation of free radicals. The injury progresses until cellular repair 
mechanisms are no longer able to regenerate keratinocytes and endothelial cells (47-48). 
This is partially confirmed by the finding, in an autoradiographic study of patient on 
hydroxyurea, of large areas of absent epidermal uptake of tritiated thymidine (49). 
Moreover most authors believe that minor traumas, very common in malleolar areas as 
caused by shoes, have a role as initiating factors in ulcer development. F ew patients, 
however, report traumas during anamnesis (50-51). Some authors have  argued that 
t he  pathogenesis of HU-associated leg ulcers is related to ischemia following 
intravascular thrombosis (52). It has been speculated that HU associated with blood 
dyscrasia in MPDs may induce a procoagulative status in the malleolar vessels and 
cause cutaneous atrophy (52). However, ulcerative skin lesions appear in MPDs after the 
blood count is well controlled by HU and, paradoxically, improve when blood dyscrasia 
recurs (53). This hypothesis is therefore no longer widely accepted. Macrocytosis is 
now considered to be a major pathogenic factor (54). The megaloblastic changes in 
erythrocyte geometry and deformability caused by HU may prevent these cells from easily 
traversing the capillaries. This may impair blood flow in the microcirculation and cause 
relative ischemia in the basal layer of the skin, which requires more oxygen for 
proliferation (55). The anoxic state and the formation of microthrombi could account for 
the extreme painfulness of these lesions. Concomitant arterial, venous or metabolic 
disease may play an additional role in the development of such wounds. In 
differential diagnosis vasculitis, cryoglobulinemia and pyoderma gangrenosum should 
be considered if typical clinical signs are demonstrated (1). A summary of significant 
anamnestic, clinical and instrumental findings relevant to the diagnosis of HU-induced 




Hydroxyurea-induced ulcers: data from a review of case reports and clinical studies 
 
In this section we present the results of a review of case reports and clinical studies 
made with the aim of summarising the published literature on HU-induced ulcers. 
MEDLI NE and  T OXL I NE da tabases  we re  sea rche d  and  82 articles were 
selected for examination: 74 case reports, 5 retrospective clinical studies, 3 prospective 
clinical studies. Data extraction focused on the following variables: med ica l  h i s to ry  
(patient gender, age, underlying pathologies; presence of venous or arterial 
insufficiency, diabetes, hypertension, report of previous trauma in the site of lesion or 
other cutaneous manifestations due to HU treatment); pharmacological  anamnesis 
(duration of HU therapy, HU daily and cumulative dose, co-use of interferon or other 
drugs); ulcer feature (site of lesions, presence of multiple or bilateral lesions, duration 
of ulcer before correct diagnosis); Therapy of the underlying disease and of the 
lesion (HU withdrawal, substitutive hematologic therapy, healing therapy, time of ulcer 
healing, outcome). 
407 cases of HU-induced leg ulcers were found d e s c r i b e d  in the literature. Leg 
ulcerations were found to be more common in females than males (193 females/164 
males/ 50 not reported). The mean patient age was 62,7 years (range 21-84). The 
population with MPDs was significantly older (mean 64 years) than SCD patients (mean 
37,3 years). Underlying pathologies were distributed as follow: 102 chronic myelogenous 
leukemia (CML) patients, 82 policytemia vera (PV) patients, 134 essential 
thrombocythemia (ET) patients, 26 myelofibrosis (MF) patients, 8 SCD patients, 4 
undifferentiated MPDs, 1 case of psoriasis (56). It is significant that a similar number  of 
cases was found among the most common MPDs. Risk factors for leg ulcers were found 
in some patients (37 case of venous insufficiency, 30 cases of arterial insufficiency, 15 
diabetic patients, 54 patients with hypertension). 24 patients had multiple risk factors. 
These data confirm the concept that HU exposure alone is sufficient to cause the 
insurgence of ulcers. However, before HU treatment is stopped, other risk factors for leg 
ulcers development should be carefully ruled out since cases of venous ulcers mimicking 
HU-induced lesions have been reported (1,57,58). 
Minor traumas before ulcer formation were reported du r ing  anamnes is  by only 27 
patients. However, the preponderance of lesions in the lateral side of the lower limb 
(75% of lesions reported to be lateral or medial) strongly suggests a role of minor 
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traumatic events in HU-induced ulcer pathogenesis. Patients can sometime refer a 
history of previous ulcers spontaneously healed during HU treatment (59). The 
coexistence of ulcer with other dermatological side effects of HU, most frequently atrophic 
skin changes and nail alterations, is quite a common finding (41) reported in 62 patients in 
our survey. 
More than half o f  t he  lesions (59,4%) were in the perimalleolar region. Heel 
ulcerations were detected in 10,7% of patients, leg lesion in the 11,5%. Toe lesions and 
the  dorsal foot were affected in 6,6% each of cases. U lcerations of Achilles tendons 
and hands (respectively 1,7% and 3,4%) were rare. Two cases of forearm ulceration (60, 
61) and another of post-operative ulcer (62) were reported. Bilateral lesions were present 
in 31% of patients showing in this way the systemic nature of HU noxa. Infection and 
malignant transformation of HU-induced leg ulcers have been reported in literature (45, 
63). 
Ulcer insurgence was associated with any daily dosage of HU. The mean dose is 
about 1,5 g. In 9 cases even the lowest dose administrable, 0.5 g/die, proved to cause 
leg ulcerations. This is in contrast with Bader, and many authors following him, who 
stated that 1 g was the lowest dose associated with HU dermatologic side effects (1). 
The mean cumulative dose was 1733 g (range 510-3960 g). The median duration of 
HU therapy before ulcer formation was about of 51 months (range 1.75 – 215 months). In 
2006 the FDA highlighted an increased risk of ulceration in patients with a history of, or 
currently receiving, interferon therapy. In our review only 20 patients reported a positive 
history for use of interferon and hydroxyurea.  
Case reports showed a median diagnosis delay of 8 months. When lesions are 
recognized as HU-induced ulcers, drug withdrawal and local wound care is the most 
common therapeutic choice (79%) with a rate of 99% of healing. However, different 
authors report treatment of HU-induced ulcer without withdrawal: dose reduction, 
even transient (64), intermittent schedules (65), accurate debridement and wound 
management (66,67) have been suggested to boost the ulcer healing process. In addition 
to pharmacologic adjustments, in order to successfully expedite wound healing, the use 
of advanced wound-care products (Table 4) has been described. Even  skin grafts and 
hyperbaric oxygen have been used successfully (46,59,76). Not stopping HU treatment in 
presence of leg ulcers appear associated with an higher risk of absent or incomplete healing 
(18%) and therefore should be advised only in patient that cannot stop HU.  
Our survey found that t he  median healing time after HU withdrawal or dose reduction 
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was 150 days (range 13 - 2,160). Many substitutive therapies have been used to replace 
HU: anagrelide, phlebotomy, aspirin, busulfan, interferon alpha, pipobroman, imatinib 
cyclophosphamide. Anagrelide too, however, can cause ulcers and a case of anagrelide-
induced relapse of a HU-induced leg ulcer has been reported (60). Recidives of ulcers 
after HU withdrawal, even after five months from stopping, were reported and ascribed to 
HU accumulation in the site of the lesion and lack of inadequate debridement of wounds 
(52, 75). 
In conclusion we present a clinical flowchart (Fig. 4) for the treatment of HU-induced ulcer 
with the aim to help correct diagnosis and effective therapy avoiding invasive and useless 




HU-induced ulcers represent a serious threat in terms of disability and loss of quality of 
life in affected patients. The ulcerations are often multiple, recidivating and painful, with 
risk of neoplastic transformation. Moreover, the literature reports a high amount of 
delayed diagnosis due to the confusing comorbidities of these patients. An increased 
awareness on the part of care providers is therefore needed to prevent this adverse effect 
and the high care cost it causes. 
To reach an efficacious early prevention, multiple strategies are possible (see Tab): firstly, 
patients with risk factors for leg ulcers such as diabetes and venous insufficiency should 
be considered, if possible, for other treatments apart from HU or should be attentively 
monitored during therapy. In addition, hematologists should inform patients and their 
relatives about the increased risk of cutaneous ulcers and photosensitivity due to HU, 
suggesting opportune leg protections and solar filters. Moreover dermatologic evaluation 
and, for suspect lesions, dermatologic consultation should be regularly performed by the 
hematologist, especially after long periods of treatment. This could help the individuation 
of early stages of the disease, allowing a precocious discontinuation of the drug. 
A recent study showed in ET subjects a correlation between poor survival and the 
development of ulcers during HU therapy. Authors proposed that underlying vasculopathy has 
predisposed these individuals to both ulcer development and cardiovascular accidents. A 
cardiovascular screening, therefore, may be advised for these patients, especially before 
switching to anagrelide, which is reported to have cardiovascular side effects (77). 
An interesting issue needing further evaluation is related to the dermatological effects of 
HU in sickle cell disease. HU for the treatment of SCD was approved in 1998 and it is 
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considered the only treatment for sickle cell disease that modifies the disease process. In 
contrast with MPDs, in which HU is given for short periods to white adult patients, HU in 
SCD is administered o n  a  lifelong b a s i s  t o  young black patients. HU-induced ulcers 
in SCD patients have been described in clinical studies (79, 80) and some case 
reports (81,82). The first of these studies found a rate of HU-induced leg ulcers (29%), 
higher than that reported in MPD patients, especially in patients with a previous history of 
leg ulcers (79). However, a randomized controlled studies and a systematic review 
(62), did not find any association between HU and leg ulcers in SCD population (78, 
83). Probably further randomized controlled studies will be necessary in order to definitely 
confirm or exclude this correlation (84). 
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Figure 1 Dermatologic adverse effects of hydroxyurea 
A: Ulcer in the ankle area in a patient with chronic myelogenous leukemia under treatment 
with HU. Notice the melanonychia affecting the first toe. 
B: Longitudinal band of the toenail after prolonged HU administration. 
 
Figure 2 Hydroxyurea induced ulcer  
Ulcer on the lateral aspect of the lower leg in a 76-year-old female patient affected by 
essential thrombocythemia after 3 years of HU-treatment. 
 
Figure 3 Hydroxyurea-induced ulcers: pathogenetic factors  
Multiple factors are involved in the genesis of HU-induced ulcers. Minor traumas, such as 
the contact with shoes in the malleolar region, act as trigger of the ulcer. Because of HU 
cytostatic effect, basal epidermal cells don‟t have the regenerative potential to repair the 
lesion. HU-induced macrocytosis impairs blood flow in the microcirculation and cause 
relative ischemia in the basal regenerating layer of the skin. Patients affected by MPDs are 
usually old and therefore vascular insufficiency and diabetes, well-known risk factors for 
ulcers, are common. HU: hydroxyurea 
 
Figure 4: Algorithm for the diagnosis and treatment of Hydroxyurea-induced leg 
ulcers. 
 
Table 1. Mucocutaneous side effects of hydroxyurea 
1. Skin atrophy , xerosis cutis, and acquired ichthyosis,. 
2. Facial and acral erythema, 
3. Palmoplantar keratoderma 
4. Alopecia 
5. Cutaneous and mucosal hyperpigmentation 
6. Dermatomyositis-like eruptions 
7. Onychodystrophy, and melanonychia  
8. Actinic keratoses and squamous cell carcinomas  
9. Cutaneous and mucosal ulcers 
Cutaneous ulcers associated with hydroxyurea therapy: a comprehensive review 
Tables
Table 2. Anamnestic, clinical and instrumental findings relevant to the  diagnosis of HU-induced ulcer. 
1. Present or past  long term and high dose treatment with HU. 
2. History of interferon  therapy. 
3. History of minor trauma in the site of lesion. 
4. History of previous ulcers during HU treatment. 
5. Presence of painful, multiple, bilateral, recidivating ulcer usually in the perimalleolar area. 
6. Presence of other form of HU mucocutaneous toxicity (See Table 1) 
7. Presence of macrocytosis. 
HU, hydroxyurea 
Cutaneous ulcers associated with hydroxyurea therapy: a comprehensive review 
Table 3. Possible histopathologic findings in hydroxyurea-induced ulcers 
1. Leukocytoclastic vasculitis 
2. Lymphocytic infiltration 
3. Formation of thrombi 
4. Thickening of vessel walls 
5. Dermal fibrosis 
6. Hyperkeratosis 
Cutaneous ulcers associated with hydroxyurea therapy: a comprehensive review 
 Table 4. Published advanced therapies in the management of hydroxyurea-induced drugs   




1 patient recovered 
1 patient improved 
Prostaglandins E1 and I2 
(44,68) 
Vasodilatation 
1 patient recovered in 1 month 




Recruitment and proliferation of 
monocytes and macrophages 
modulating cytokine production 
3 patients recovered in 2 weeks 
1 patient recovered in 1 month 
Human skin equivalent 
(63,70) 
Skin substitution 
1 patient recovered in 3 weeks 
1 patient improved 
Manuka honey and hydrocolloid 
dressing 
(45) 
Antibacterial activity 1 patient recovered in 3 weeks  




1 patient recovered in 2 weeks 
1 patient showed no improvement 




2 patients recovered in 2 months 
1 patient improved 
Sodium hyaluronate 
and bacterial collagenase 
(75) 
Enzymatic debridement 1 patient recovered in 3 months 
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Table 5. Preventive strategies in HU induced ulcer management 
1. Avoid, if other treatment is possible, HU treatment in patients with high risk factors for ulcer development. 
2. Inform the patients and their relatives about the mucocutaneous toxicity of HU-treatment and advice 
immediate medical alert in case of suspected lesions. 
3. In high-risk patients, suggest opportune leg protections and solar filters. 
4. Patients should undergo regular dermatologic evaluations, especially after long term treatment. 
5. A cardiovascular check-up could be advised in patients who developed ulcer after HU-treatment 
 HU, hydroxyurea 
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